Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2018-12-27 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于召开2019年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2019 first extraordinary general meeting of shareholders for 华兰生物工程股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed (notably a restricted stock incentive plan), registration details, and proxy authorization forms. There is no financial data or results reported, nor is it a transcript or presentation. It is a formal announcement to shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length and content confirm it is not a brief announcement or a report publication announcement but a full notice with voting instructions and proxy forms.
2018-12-27 Chinese
独立董事公开征集委托投票权报告书
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled as an "Independent Director Public Solicitation of Proxy Voting Rights Report" for a 2019 first extraordinary general meeting (临时股东大会) of Hualan Biological Engineering Co., Ltd. It details the solicitation of proxy votes by an independent director for a specific agenda item related to a 2018 restricted stock incentive plan revision. The document includes legal disclaimers, company basic information, the solicitation process, and a proxy authorization form. It is not a financial report, earnings release, or management discussion. It is a formal report related to proxy solicitation for a shareholder meeting, which fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 4419 characters, which is substantive and contains detailed procedural and legal information about proxy solicitation, not merely an announcement or a brief notice. Therefore, the best classification is PSI with high confidence.
2018-12-27 Chinese
第六届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of 华兰生物工程股份有限公司 regarding resolutions passed at the 14th meeting of the 6th board. It includes details about approval of amendments to the 2018 restricted stock incentive plan and the scheduling of the 2019 first extraordinary shareholders' meeting. The content focuses on board decisions and meeting resolutions, with no financial statements or earnings data. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement, but a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is a direct announcement of board decisions, not a report publication or regulatory filing. Confidence is high due to clear board meeting context and resolution content.
2018-12-27 Chinese
2018年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2018 first extraordinary general meeting of shareholders of 华兰生物工程股份有限公司. It details the meeting date, attendance, voting methods, voting results on several proposals, and includes a legal opinion confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes at a general meeting, including detailed vote counts and percentages. There is no indication that this is a full report or presentation, but rather an official announcement of voting results. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 3112 characters, which is consistent with an announcement rather than a full report.
2018-12-21 Chinese
关于2018年限制性股票激励计划内幕信息知情人买卖公司股票的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading related to a 2018 restricted stock incentive plan. It details the investigation of insider trading activities by persons aware of the plan, referencing regulatory requirements and confirming no insider trading occurred during the specified period. The document is a compliance and regulatory disclosure about insider dealings, not a financial report, earnings release, or management discussion. It does not announce changes in board or management, nor is it a voting result or capital update. It fits best as a Regulatory Filing (RNS) because it is a regulatory compliance disclosure that does not fit other specific categories.
2018-12-21 Chinese
2018年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and proceedings of a 2018 first extraordinary general meeting (临时股东大会) of Huaran Bioengineering Co., Ltd. It details the legality of the meeting's convening, attendance, proposals, voting procedures, and results. The document includes detailed voting results and confirms the validity of the resolutions passed at the shareholders' meeting. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or a report publication announcement. The document is focused on the official voting results and legality of the shareholder meeting resolutions, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2708 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the best classification is DVA with high confidence.
2018-12-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.